GBP116.00
1.58% day before yesterday
London, Feb 07, 05:41 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Stock price

GBP116.00
+9.32 8.74% 1M
-10.12 8.03% 6M
+11.32 10.81% YTD
+13.35 13.01% 1Y
+37.83 48.40% 3Y
+47.92 70.39% 5Y
+83.85 260.80% 10Y
London, Closing price Fri, Feb 07 2025
-1.86 1.58%
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

Key metrics

Market capitalization GBP179.87b
Enterprise Value GBP199.61b
P/E (TTM) P/E ratio 32.59
EV/FCF (TTM) EV/FCF 24.81
EV/Sales (TTM) EV/Sales 4.72
P/S ratio (TTM) P/S ratio 4.25
P/B ratio (TTM) P/B ratio 5.92
Dividend yield 2.48%
Last dividend (FY24) GBP2.88
Revenue growth (TTM) Revenue growth 14.82%
Revenue (TTM) Revenue GBP42.31b
EBIT (operating result TTM) EBIT GBP8.54b
Free Cash Flow (TTM) Free Cash Flow GBP8.05b
Cash position GBP4.51b
EPS (TTM) EPS GBP3.56
P/E forward 22.03
P/S forward 3.93
EV/Sales forward 4.36
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

27x Buy
82%
6x Hold
18%

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

Buy
82%
Hold
18%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
42,307 42,307
15% 15%
100%
- Direct Costs 11,739 11,739
18% 18%
28%
30,568 30,568
14% 14%
72%
- Selling and Administrative Expenses 7,246 7,246
13% 13%
17%
- Research and Development Expense 9,556 9,556
16% 16%
23%
13,767 13,767
33% 33%
33%
- Depreciation and Amortization 5,225 5,225
20% 20%
12%
EBIT (Operating Income) EBIT 8,542 8,542
43% 43%
20%
Net Profit 5,515 5,515
15% 15%
13%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Neutral
PRNewsWire
one day ago
BENSALEM, Pa. , Feb. 7, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Neutral
PRNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson dire...
Positive
The Motley Fool
2 days ago
A fresh earnings release was the news development powering AstraZeneca's (AZN 2.01%) share price higher on Thursday. Investors were clearly impressed by the pharmaceutical company's numbers, as the stock closed the day more than 2% higher in value.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Founded 1992
Website www.astrazeneca.co.uk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today